Shaker Heights, United States
Cellular Technology Limited — CTL, founded in 1998, is a frontrunner in ELISPOT technology for immune monitoring, positioning itself as a key player in both the Biotechnology and Information Technology sectors. With a firm mission of “Elevating ELISPOT to an Exact Science,” the company serves over 2,000 clients globally, addressing the needs of academia and industry alike.
Headquartered in the United States, CTL is recognized for its state-of-the-art Contract Laboratory services, offering a wide range of assays - from ELISPOT and ELISA to FACS and Proliferation. Key offerings include the industry’s largest Cryopreserved PBMC Library, a suite of ImmunoSpot® Kits, and advanced ImmunoSpot® and BioSpot® Analyzers. Notably, their CLIA-certified, GLP-compliant laboratory processes up to 450 samples weekly, demonstrating significant operational capacity.
While CTL has not disclosed recent investments, its sustained market presence and innovative solutions underline potential for growth, making it a promising consideration for investors focused on niche advancements in immune monitoring technology.
